Business
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical d
About this update from Acrivon Therapeutics, Inc.
[{"type":"image","alt":"Acrivon Therapeutics, Inc","displaySize":"","headline":null,"caption":"Acrivon Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/18842H0LzLmEExp9Uy8VVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6","width":300,"height":160}},"lazy":false},{"type":"text","content":"WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates in January 2026.","length":618,"tagName":"p"},{"type":"text","content":"Topics will include:","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Updated interim ACR-368 clinical data from the ongoing registrational-intent Phase 2b study as well as an update on the additional recently initiated tumor biopsy-independent Phase 2b arm, and the planned confirmatory Phase 3 trial","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial clinical data from the ongoing Phase 1 study of ACR-2316, a potential first- and best-in-class WEE1/PKMYT1 inhibitor, including safety data, dosing regimen, and early clinical activity across AP3-prioritized solid tumor types","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"Nomination of new preclinical development candidate, including target disclosure, for Acrivon’s AP3-driven cell cycle program","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":589,"olType":false},{"type":"text","content":"About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The pl...